RNA干扰敲低GliPR1在体外和体内发挥抗胶质瘤作用
研究利用shRNA敲低胶质母细胞瘤细胞中的GliPR1,体外评估增殖与克隆存活,体内在裸鼠中观察肿瘤生长与生存。结果显示敲低GliPR1可抑制增殖、降低克隆存活、诱导凋亡,并减小肿瘤体积和脑部肿瘤面积、延长生存,提示GliPR1可能是有潜力的治疗靶点。
要点
- GliPR1敲低抑制胶质瘤细胞增殖和克隆存活并诱导凋亡。
- 裸鼠体内敲低GliPR1可减小皮下肿瘤体积和脑部肿瘤面积。
- 稳定敲低GliPR1可显著延长颅内荷瘤裸鼠生存(41 vs 26天,P<0.001)。
核心结论
- 敲低GliPR1在体外抑制胶质瘤细胞增殖和克隆存活并诱导凋亡,在体内减小肿瘤生长并延长生存,提示GliPR1可能是有潜力的治疗靶点。
研究设计与样本
- 实验使用转导GliPR1 shRNA(sh#301、sh#258)的人胶质母细胞瘤细胞系,通过慢病毒TetOn-shRNA载体实现多西环素依赖的诱导性敲低,或通过组成型逆转录病毒shRNA载体实现稳定敲低。
主要发现
- 多西环素依赖敲低时,shGliPR1转导的U87-MG克隆在多西环素存在下较无多西环素时细胞增殖减少。
- 稳定敲低时,shGliPR1转导的U87-MG、A172和U343-MG多克隆细胞较对照shLuc转导细胞克隆存活下降并诱导凋亡(早期凋亡细胞比例更高)。
- 荷瘤裸鼠中,多西环素依赖敲低时,皮下和颅内移植U87-MG克隆980-5(转导GliPR1 sh#301)后,多西环素处理小鼠较未处理小鼠皮下肿瘤体积和脑部肿瘤面积减小。
- 稳定敲低时,颅内移植转导GliPR1 sh#258的多克隆U87-MG细胞的裸鼠较对照shLuc转导细胞移植鼠生存显著延长(41 vs 26天;P<0.001)。
临床怎么用
- GliPR1敲低在胶质母细胞瘤模型中显示抗增殖、促凋亡和延长生存的作用,支持进一步评估GliPR1作为治疗靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: In human glioblastomas, glioma pathogenesis-related protein1 (GliPR1) is overexpressed and appears to be an oncoprotein. We investigated whether GliPR1 knockdown in glioma cells by RNA interference exerts anti-glioma effects. METHODS: Experiments used human glioblastoma cell lines transduced with GliPR1 shRNA (sh#301, sh#258). Transduction produced stringent doxycycline-dependent GliPR1 knockdown in clones (via lentiviral "all-in-one" TetOn-shRNA vector) or stable GliPR1 knockdown in polyclonal cells (via constitutive retroviral-shRNA vector). In vitro assessments included cellular proliferation and clonogenic survival. In vivo assessments in tumor-bearing nude mice included tumor growth and survival. RESULTS: Using doxycycline-dependent GliPR1 knockdown, shGliPR1-transduced U87-MG clones demonstrated reductions in cellular proliferation in the presence versus absence of doxycycline. Using stable GliPR1 knockdown, polyclonal shGliPR1-transduced U87-MG, A172, and U343-MG cells consistently showed decreased clonogenic survival and induced apoptosis (higher proportion of early apoptotic cells) compared to control shLuc-transduced cells. In tumor-bearing nude mice, using doxycycline-dependent GliPR1 knockdown, subcutaneous and cranial transplantation of the U87-MG clone 980-5 (transduced with GliPR1 sh#301) resulted in reduced subcutaneous tumor volume and cerebral tumor area in doxycycline-treated mice versus those left untreated. Using stable GliPR1 knockdown, nude mice cranially transplanted with polyclonal U87-MG cells transduced with GliPR1 sh#258 had significantly prolonged survival compared to mice cranially transplanted with control shLuc-transduced cells (41 versus 26 days; P < 0.001). CONCLUSION: GliPR1 knockdown in glioma cells decreased cellular proliferation, decreased clonogenic survival, and induced apoptosis in vitro, and reduced glioblastoma tumor growth and prolonged survival in vivo. These findings support that GliPR1 may have potential value as a therapeutic target.
引用
- Scheuring UJ, Ritter S, Martin D, et al. GliPR1 knockdown by RNA interference exerts anti-glioma effects in vitro and in vivo. J Neurooncol. 2021. PMID: 33856615. doi:10.1007/s11060-021-03737-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。